Advisory committee will discuss tools for Alzheimer’s diagnosis
Executive Summary
The Peripheral and Central Nervous System Drugs Advisory Committee will meet Oct. 23 to discuss the development of radionuclide imaging for amyloid detection to assist in diagnosing Alzheimer's disease. The buildup of amyloid plaque may be a key characteristic of the disease, but so far no company has successfully developed an anti-amyloid therapy (1"The Pink Sheet," Aug. 4, 2008, p. 15). Firms unveiled data on their respective agents at the International Conference on Alzheimer's Disease. Phase II data from Lilly's anti-amyloid beta monoclonal antibody LY2062430 showed no change in patients' cognitive score or the amount of plaque in the brain, and a Phase II study of Wyeth/Elan's bapineuzumab, a monoclonal antibody thought to induce an immune response to clear beta amyloid plaque buildup in the brain, failed to meet its primary efficacy endpoints
You may also be interested in...
Anti-Amyloid Still All The RAGE At Alzheimer’s Disease Conference
A little more than a week after an article published in The Lancet raised questions about the assumption that removing amyloid plaque is key to modifying Alzheimer's disease - an assumption upon which most drug makers are pinning their hopes - Wyeth, Lilly and Pfizer unveiled data on their respective agents at the International Conference on Alzheimer's Disease in Chicago
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.